Raphaël Giraud1,2,3, David Legouis1,2,4,5, Benjamin Assouline1,2,3, Amandine De Charriere1,2,3, Dumeng Decosterd6, Marie-Eve Brunner6, Mallory Moret-Bochatay7, Thierry Fumeaux2,7, Karim Bendjelid1,2,3. 1. Intensive Care Unit, Geneva University Hospitals, Geneva, Switzerland. 2. Faculty of Medicine, University of Geneva, Geneva, Switzerland. 3. Geneva Hemodynamic Research Group, Geneva, Switzerland. 4. Laboratory of Nephrology, Department of Medicine, University Hospitals of Geneva, Geneva, Switzerland. 5. Department of Cell Physiology, Faculty of Medicine, University of Geneva, Geneva, Switzerland. 6. Intensive Care Unit, Réseau Hospitalier Neuchâtelois, Site de Pourtalès, Neuchatel, Switzerland. 7. Intensive Care Unit, Groupement Hospitalier de l'Ouest Lémanique, Hôpital de zone de Nyon, Nyon, Switzerland.
Abstract
INTRODUCTION: Current knowledge on the use of extracorporeal membrane oxygenation (ECMO) in COVID-19 remains limited to small series and registry data. In the present retrospective monocentric study, we report on our experience, our basic principles, and our results in establishing and managing ECMO in critically ill COVID-19 patients. METHODS: A cohort study was conducted in patients with severe acute respiratory distress syndrome (ARDS) related to COVID-19 pneumonia admitted to the ICU of the Geneva University Hospitals and supported by VV-ECMO from March 14 to May 31. The VV-ECMO implementation criteria were defined according to an institutional algorithm validated by the local crisis unit and the Swiss Society of Intensive Care Medicine. RESULTS: Out of 137 ARDS patients admitted to our ICU, 10 patients (age 57 ± 4 years, BMI 31.5 ± 5 kg/m2 , and SAPS II score 56 ± 3) were put on VV-ECMO. The mean duration of mechanical ventilation before ECMO and mean time under ECMO were 7 ± 3 days and 19 ± 11 days, respectively. The ICU and hospital length of stay were 26 ± 11 and 35 ± 10 days, respectively. The survival rate for patients on ECMO was 40%. The comparative analysis between survivors and non-survivors highlighted that survivors had a significantly shorter mechanical ventilation duration before ECMO (4 ± 2 days vs. 9 ± 2 days, p = 0.01). All the patients who had more than 150 h of mechanical ventilation before the application of ECMO ultimately died. CONCLUSION: The present results suggest that VV-ECMO can be safely utilized in appropriately selected COVID-19 patients with refractory hypoxemia. The main information for clinicians is that late VV-ECMO therapy (i.e., beyond the seventh day of mechanical ventilation) seems futile.
INTRODUCTION: Current knowledge on the use of extracorporeal membrane oxygenation (ECMO) in COVID-19 remains limited to small series and registry data. In the present retrospective monocentric study, we report on our experience, our basic principles, and our results in establishing and managing ECMO in critically ill COVID-19 patients. METHODS: A cohort study was conducted in patients with severe acute respiratory distress syndrome (ARDS) related to COVID-19 pneumonia admitted to the ICU of the Geneva University Hospitals and supported by VV-ECMO from March 14 to May 31. The VV-ECMO implementation criteria were defined according to an institutional algorithm validated by the local crisis unit and the Swiss Society of Intensive Care Medicine. RESULTS: Out of 137 ARDS patients admitted to our ICU, 10 patients (age 57 ± 4 years, BMI 31.5 ± 5 kg/m2 , and SAPS II score 56 ± 3) were put on VV-ECMO. The mean duration of mechanical ventilation before ECMO and mean time under ECMO were 7 ± 3 days and 19 ± 11 days, respectively. The ICU and hospital length of stay were 26 ± 11 and 35 ± 10 days, respectively. The survival rate for patients on ECMO was 40%. The comparative analysis between survivors and non-survivors highlighted that survivors had a significantly shorter mechanical ventilation duration before ECMO (4 ± 2 days vs. 9 ± 2 days, p = 0.01). All the patients who had more than 150 h of mechanical ventilation before the application of ECMO ultimately died. CONCLUSION: The present results suggest that VV-ECMO can be safely utilized in appropriately selected COVID-19 patients with refractory hypoxemia. The main information for clinicians is that late VV-ECMO therapy (i.e., beyond the seventh day of mechanical ventilation) seems futile.
Authors: Laveena Munshi; Allan Walkey; Ewan Goligher; Tai Pham; Elizabeth M Uleryk; Eddy Fan Journal: Lancet Respir Med Date: 2019-01-11 Impact factor: 30.700
Authors: Asishana A Osho; Philicia Moonsamy; Kathryn A Hibbert; Kenneth T Shelton; John M Trahanas; Rizwan Q Attia; Jordan P Bloom; Michael T Onwugbufor; David A D'Alessandro; Mauricio A Villavicencio; Thoralf M Sundt; Jerome C Crowley; Yuval Raz; Masaki Funamoto Journal: Ann Surg Date: 2020-08 Impact factor: 12.969
Authors: Matthieu Schmidt; David Hajage; Guillaume Lebreton; Antoine Monsel; Guillaume Voiriot; David Levy; Elodie Baron; Alexandra Beurton; Juliette Chommeloux; Paris Meng; Safaa Nemlaghi; Pierre Bay; Pascal Leprince; Alexandre Demoule; Bertrand Guidet; Jean Michel Constantin; Muriel Fartoukh; Martin Dres; Alain Combes Journal: Lancet Respir Med Date: 2020-08-13 Impact factor: 30.700
Authors: Valmiki Maharaj; Tamas Alexy; Arianne C Agdamag; Rajat Kalra; Bellony N Nzemenoh; Victoria Charpentier; Jason A Bartos; Melissa E Brunsvold; Demetris Yannopoulos Journal: ASAIO J Date: 2022-02-07 Impact factor: 3.826
Authors: Saad Alhumaid; Abbas Al Mutair; Header A Alghazal; Ali J Alhaddad; Hassan Al-Helal; Sadiq A Al Salman; Jalal Alali; Sana Almahmoud; Zulfa M Alhejy; Ahmad A Albagshi; Javed Muhammad; Amjad Khan; Tarek Sulaiman; Maha Al-Mozaini; Kuldeep Dhama; Jaffar A Al-Tawfiq; Ali A Rabaan Journal: Eur J Med Res Date: 2021-12-09 Impact factor: 2.175
Authors: Ruslan Natanov; Elena R Kunkel; Olaf Wiesner; Axel Haverich; Bettina Wiegmann; Stefan Rümke; Christian Kühn Journal: Perfusion Date: 2022-07-04 Impact factor: 1.581